EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 20 / No 12 (Décembre 2004) Med Sci (Paris), 20 12 (2004) 1125-1130 References
Free Access
Issue
Med Sci (Paris)
Volume 20, Number 12, Décembre 2004
Page(s) 1125 - 1130
Section M/S revues
DOI https://doi.org/10.1051/medsci/200420121125
Published online 15 December 2004
  1. Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315 : 550–4. [Google Scholar]
  2. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56 : 100–4. [Google Scholar]
  3. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105 : 3–7. [Google Scholar]
  4. Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289 : 1938–42. [Google Scholar]
  5. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002; 109 : 275–82. [Google Scholar]
  6. Dorey K, Engen JR, Kretzschmar J, et al. Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene 2001; 20 : 8075–84. [Google Scholar]
  7. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348 : 994–1004. [Google Scholar]
  8. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571 : diverse mechanisms of resistance. Blood 2000; 96 : 1070–9. [Google Scholar]
  9. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293 : 876–80. [Google Scholar]
  10. Le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95 : 1758–66. [Google Scholar]
  11. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16 : 2190–6. [Google Scholar]
  12. Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293 : 2163. [Google Scholar]
  13. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101 : 2368–73. [Google Scholar]
  14. Ferrao PT, Frost MJ, Siah SP, et al. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of Imatinib (STI571) in vitro. Blood 2003; 102 : 4499–503. [Google Scholar]
  15. Hofmann WK, de Vos S, Elashoff D, et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles : a gene-expression study. Lancet 2002; 359 : 481–6. [Google Scholar]
  16. Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000; 92 : 1641–50. [Google Scholar]
  17. Jorgensen HG, Elliott MA, Allan EK, et al. Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 2002; 99 : 713–5. [Google Scholar]
  18. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003; 9 : 625–32. [Google Scholar]
  19. Le Coutre P, Kreuzer KA, Na IK, et al. Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 2002; 28 : 75–85. [Google Scholar]
  20. Larghero J, Leguay T, Mourah S, et al. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem Pharmacol 2003; 66 : 1907–13. [Google Scholar]
  21. Gambarcorti-Passerini C, Gunby R, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4 : 75–85. [Google Scholar]
  22. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101 : 690–8. [Google Scholar]
  23. Barthe C, Cony-Makhoul P, Melo JV, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293 : 2163. [Google Scholar]
  24. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102 : 276–83. [Google Scholar]
  25. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2 : 117–25. [Google Scholar]
  26. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100 : 1014–8. [Google Scholar]
  27. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/Imatinib resistance revealed by mutagenesis of bcr-abl. Cell 2003; 112 : 831–43. [Google Scholar]
  28. Corbin AS, La Rosee P, Stoffregen EP, et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101 : 4611–4. [Google Scholar]
  29. Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002; 99 : 10700–5. [Google Scholar]
  30. Barthe C, Gharbi MJ, Lagarde V, et al. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. Br J Haematol 2002; 119 : 109–11. [Google Scholar]
  31. Roche-Lestienne C, Lai JL, Darre S, et al. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N Engl J Med 2003; 348 : 2265–6. [Google Scholar]
  32. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62 : 4236–43. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.